Nancy Joann Johnson Sells 801 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 801 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $124.91, for a total value of $100,052.91. Following the completion of the transaction, the insider directly owned 21,099 shares of the company’s stock, valued at $2,635,476.09. This trade represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54.
• On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The stock was sold at an average price of $99.28, for a total transaction of $339,339.04.

Billiontoone Trading Down 4.3%

Shares of Billiontoone stock opened at $118.04 on Wednesday. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The company has a fifty day simple moving average of $97.67 and a 200-day simple moving average of $88.26. The stock has a market cap of $5.43 billion and a price-to-earnings ratio of 214.62. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. During the same quarter in the prior year, the business earned ($0.39) earnings per share. Billiontoone’s revenue was up 83.8% compared to the same quarter last year. On average, equities analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BLLN. Baillie Gifford & Co. purchased a new stake in Billiontoone in the 4th quarter valued at approximately $103,786,000. Massachusetts Financial Services Co. MA acquired a new position in Billiontoone during the 4th quarter worth approximately $13,373,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Billiontoone during the 4th quarter worth approximately $1,348,000. UBS Group AG acquired a new stake in shares of Billiontoone in the 4th quarter valued at approximately $2,586,000. Finally, Seven Grand Managers LLC acquired a new stake in shares of Billiontoone in the 4th quarter valued at approximately $2,046,000.

Analyst Ratings Changes

Several research firms have recently weighed in on BLLN. BTIG Research reduced their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. lifted their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, Guggenheim began coverage on Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Billiontoone currently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.